Fundamental Analysis of PHAXIAM Therapeutics SA(NASDAQ:PHXM) stock

Fundamental Rating

Taking everything into account, PHXM scores 2 out of 10 in our fundamental rating. PHXM was compared to 573 industry peers in the Biotechnology industry. PHXM may be in some trouble as it scores bad on both profitability and health. PHXM has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

PHXM had negative earnings in the past year.

PHXM had a negative operating cash flow in the past year.

1.2 Ratios

The Return On Assets of PHXM (-0.35%) is better than 93.60% of its industry peers.

Looking at the Return On Equity, with a value of -0.62%, PHXM belongs to the top of the industry, outperforming 93.94% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-0.35%
ROE	-0.62%
ROIC	N/A

ROA(3y)-57.41%

ROA(5y)N/A

ROE(3y)-170.88%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHXM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PHXM does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for PHXM remains at a similar level compared to 1 year ago.

PHXM has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -1.09, we must say that PHXM is in the distress zone and has some risk of bankruptcy.

PHXM's Altman-Z score of -1.09 is in line compared to the rest of the industry. PHXM outperforms 52.36% of its industry peers.

PHXM has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.

PHXM has a Debt to Equity ratio of 0.30. This is in the lower half of the industry: PHXM underperforms 71.89% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.3
Debt/FCF	N/A
Altman-Z	-1.09

ROIC/WACCN/A

WACC4.88%

2.3 Liquidity

PHXM has a Current Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.

PHXM has a worse Current ratio (1.78) than 80.13% of its industry peers.

A Quick Ratio of 1.78 indicates that PHXM should not have too much problems paying its short term obligations.

PHXM has a Quick ratio of 1.78. This is in the lower half of the industry: PHXM underperforms 78.62% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.78
Quick Ratio	1.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.68% over the past year.

Looking at the last year, PHXM shows a very strong growth in Revenue. The Revenue has grown by 59.04%.

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-1025.16%

Revenue 1Y (TTM)59.04%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-70.86%

3.2 Future

The Earnings Per Share is expected to grow by 23.84% on average over the next years. This is a very strong growth

PHXM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.

EPS Next Y77.73%

EPS Next 2Y36.72%

EPS Next 3Y23.84%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5Y-18.92%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PHXM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year PHXM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as PHXM's earnings are expected to grow with 23.84% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y36.72%

EPS Next 3Y23.84%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PHXM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PHAXIAM Therapeutics SA

NASDAQ:PHXM (3/8/2024, 8:27:22 PM)

After market: 3.1 0 (0%)

3.1

-0.02 (-0.64%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap18.83M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.35%
ROE	-0.62%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0.3
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.78
Quick Ratio	1.78
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)99.68%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y77.73%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)59.04%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PHAXIAM Therapeutics SA (PHXM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens